Cargando…

Cost-effectiveness of New Oral Anticoagulants for the Prevention of Stroke in Patients with Atrial Fibrillation in Low and Middle-Income Countries: A Systematic Review

Background: Low- and middle-income (LMICs) countries are facing with a high incidence of cardiovascular diseases and limited resources for confronting these diseases. Atrial fibrillation(AF) is the most common cardiac arrhythmia in the world that is associated with significant morbidity and mortalit...

Descripción completa

Detalles Bibliográficos
Autores principales: Souresrafil, Aghdas, Abutorabi, Ali, Peighambari, Mohammad Mehdi, Noohi, Fereidoun, Haghjoo, Majid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Iran University of Medical Sciences 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9386746/
https://www.ncbi.nlm.nih.gov/pubmed/35999924
http://dx.doi.org/10.47176/mjiri.36.6
_version_ 1784769879795040256
author Souresrafil, Aghdas
Abutorabi, Ali
Peighambari, Mohammad Mehdi
Noohi, Fereidoun
Haghjoo, Majid
author_facet Souresrafil, Aghdas
Abutorabi, Ali
Peighambari, Mohammad Mehdi
Noohi, Fereidoun
Haghjoo, Majid
author_sort Souresrafil, Aghdas
collection PubMed
description Background: Low- and middle-income (LMICs) countries are facing with a high incidence of cardiovascular diseases and limited resources for confronting these diseases. Atrial fibrillation(AF) is the most common cardiac arrhythmia in the world that is associated with significant morbidity and mortality. This study assessed cost-effectiveness studies of novel oral anticoagulants(NOACs) compared to Warfarin for the prevention of stroke in patients with AF in LMICs. Methods: In this systematic review study, electronic databases were searched for economic evaluation studies about NOACs cost-effectiveness conducted in LMICs between 2008 and 2019. The selection of studies for review was also based on the PICO (population, intervention, comparison, and outcomes) guidelines. In this study, the population was restricted to patients with atrial fibrillation living in LMICs. We identified three types of drugs (apixaban, rivaroxaban, dabigatran, and edoxaban) as interventions and warfarin as the comparison therapy. Quality of Health Economic Studies checklist was used to evaluate the quality of the included articles. Results: Sixteen articles were extracted, including four cost-effectiveness analyses and two cost-utility analyses. QHES scores ranged from 58 to 87.5 out of a possible 100 points, with a mean score of 77.34. The results of the study showed that from a social perspective, Edoxaban is the most cost-effective therapeutic option compared to warfarin and other NOACs, but Warfarin was much more cost-effective than Rivaroxaban and Apixaban. Furthermore, NOACs were more cost-effective than warfarin from the payer perspective, but from the health system perspective, all NOACs were dominated by warfarin. Conclusion: The present systematic review demonstrates that from a social perspective, Edoxaban is the optimal alternative to warfarin other NOACs for stroke prevention in patients with AF in (LMICs). one study was found on the economic evaluation of NOACs and warfarin in patients with AF in low-income countries, so further research on the economic evaluation of these drugs is recommended.
format Online
Article
Text
id pubmed-9386746
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Iran University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-93867462022-08-22 Cost-effectiveness of New Oral Anticoagulants for the Prevention of Stroke in Patients with Atrial Fibrillation in Low and Middle-Income Countries: A Systematic Review Souresrafil, Aghdas Abutorabi, Ali Peighambari, Mohammad Mehdi Noohi, Fereidoun Haghjoo, Majid Med J Islam Repub Iran Systematic Review Article Background: Low- and middle-income (LMICs) countries are facing with a high incidence of cardiovascular diseases and limited resources for confronting these diseases. Atrial fibrillation(AF) is the most common cardiac arrhythmia in the world that is associated with significant morbidity and mortality. This study assessed cost-effectiveness studies of novel oral anticoagulants(NOACs) compared to Warfarin for the prevention of stroke in patients with AF in LMICs. Methods: In this systematic review study, electronic databases were searched for economic evaluation studies about NOACs cost-effectiveness conducted in LMICs between 2008 and 2019. The selection of studies for review was also based on the PICO (population, intervention, comparison, and outcomes) guidelines. In this study, the population was restricted to patients with atrial fibrillation living in LMICs. We identified three types of drugs (apixaban, rivaroxaban, dabigatran, and edoxaban) as interventions and warfarin as the comparison therapy. Quality of Health Economic Studies checklist was used to evaluate the quality of the included articles. Results: Sixteen articles were extracted, including four cost-effectiveness analyses and two cost-utility analyses. QHES scores ranged from 58 to 87.5 out of a possible 100 points, with a mean score of 77.34. The results of the study showed that from a social perspective, Edoxaban is the most cost-effective therapeutic option compared to warfarin and other NOACs, but Warfarin was much more cost-effective than Rivaroxaban and Apixaban. Furthermore, NOACs were more cost-effective than warfarin from the payer perspective, but from the health system perspective, all NOACs were dominated by warfarin. Conclusion: The present systematic review demonstrates that from a social perspective, Edoxaban is the optimal alternative to warfarin other NOACs for stroke prevention in patients with AF in (LMICs). one study was found on the economic evaluation of NOACs and warfarin in patients with AF in low-income countries, so further research on the economic evaluation of these drugs is recommended. Iran University of Medical Sciences 2022-02-09 /pmc/articles/PMC9386746/ /pubmed/35999924 http://dx.doi.org/10.47176/mjiri.36.6 Text en © 2022 Iran University of Medical Sciences https://creativecommons.org/licenses/by-nc-sa/1.0/This is an open-access article distributed under the terms of the Creative Commons Attribution NonCommercial-ShareAlike 1.0 License (CC BY-NC-SA 1.0), which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.
spellingShingle Systematic Review Article
Souresrafil, Aghdas
Abutorabi, Ali
Peighambari, Mohammad Mehdi
Noohi, Fereidoun
Haghjoo, Majid
Cost-effectiveness of New Oral Anticoagulants for the Prevention of Stroke in Patients with Atrial Fibrillation in Low and Middle-Income Countries: A Systematic Review
title Cost-effectiveness of New Oral Anticoagulants for the Prevention of Stroke in Patients with Atrial Fibrillation in Low and Middle-Income Countries: A Systematic Review
title_full Cost-effectiveness of New Oral Anticoagulants for the Prevention of Stroke in Patients with Atrial Fibrillation in Low and Middle-Income Countries: A Systematic Review
title_fullStr Cost-effectiveness of New Oral Anticoagulants for the Prevention of Stroke in Patients with Atrial Fibrillation in Low and Middle-Income Countries: A Systematic Review
title_full_unstemmed Cost-effectiveness of New Oral Anticoagulants for the Prevention of Stroke in Patients with Atrial Fibrillation in Low and Middle-Income Countries: A Systematic Review
title_short Cost-effectiveness of New Oral Anticoagulants for the Prevention of Stroke in Patients with Atrial Fibrillation in Low and Middle-Income Countries: A Systematic Review
title_sort cost-effectiveness of new oral anticoagulants for the prevention of stroke in patients with atrial fibrillation in low and middle-income countries: a systematic review
topic Systematic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9386746/
https://www.ncbi.nlm.nih.gov/pubmed/35999924
http://dx.doi.org/10.47176/mjiri.36.6
work_keys_str_mv AT souresrafilaghdas costeffectivenessofneworalanticoagulantsforthepreventionofstrokeinpatientswithatrialfibrillationinlowandmiddleincomecountriesasystematicreview
AT abutorabiali costeffectivenessofneworalanticoagulantsforthepreventionofstrokeinpatientswithatrialfibrillationinlowandmiddleincomecountriesasystematicreview
AT peighambarimohammadmehdi costeffectivenessofneworalanticoagulantsforthepreventionofstrokeinpatientswithatrialfibrillationinlowandmiddleincomecountriesasystematicreview
AT noohifereidoun costeffectivenessofneworalanticoagulantsforthepreventionofstrokeinpatientswithatrialfibrillationinlowandmiddleincomecountriesasystematicreview
AT haghjoomajid costeffectivenessofneworalanticoagulantsforthepreventionofstrokeinpatientswithatrialfibrillationinlowandmiddleincomecountriesasystematicreview